Literature DB >> 17046481

Are one or two dangerous? Quinine and quinidine exposure in toddlers.

Michelle Huston1, Michael Levinson.   

Abstract

Quinine and quinidine have been cited as drugs that may cause significant morbidity and mortality in toddlers who ingest one or two pills. The use of both of these drugs has declined in the United States since the 1980s. A review of the literature and Poison Control data reveals that large quinine and quinidine ingestions, although rare in this country, may lead to severe toxicity and death related to cardiovascular and neurological effects in both children and adults. Although the majority of cases of quinine and quinidine toxicity in toddlers occur after ingestions of more than two pills, a single report each of severe toxicity after the equivalent of an ingestion of two pills or less by a toddler exists for both quinine and quinidine. Although the risk to the toddler exposed to one or two tablets seems to be small, triage to an Emergency Department is warranted after quinidine ingestion of any amount and after quinine ingestion that exceeds the age-appropriate therapeutic dose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046481     DOI: 10.1016/j.jemermed.2006.07.018

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

1.  Chemotherapeutics challenges in developing effective treatments for the endemic malarias.

Authors:  J Kevin Baird
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-02-17       Impact factor: 4.077

2.  The antimalarial drug quinine disrupts Tat2p-mediated tryptophan transport and causes tryptophan starvation.

Authors:  Combiz Khozoie; Richard J Pleass; Simon V Avery
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

3.  Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.

Authors:  Ingmar Lautenschläger; Inéz Frerichs; Heike Dombrowsky; Jürgen Sarau; Torsten Goldmann; Karina Zitta; Martin Albrecht; Norbert Weiler; Stefan Uhlig
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.